Roth Capital analyst Adam Walsh downgraded Apellis (APLS) to Neutral from Buy with a price target of $41, up from $31, following Biogen’s (BIIB) announced acquisition at $41 per share in cash. Roth recommends tendering shares into the offer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Biogen price target raised to $275 from $250 at Oppenheimer
- Apellis downgraded to Neutral from Buy at H.C. Wainwright
- Apellis: Hold Rating as Biogen Takeout Caps Upside and CVR Payouts Look Unlikely Under Conservative Syfovre Outlook
- Apellis downgraded to Neutral from Overweight at JPMorgan